TIDMMXC
RNS Number : 1272S
MGC Pharmaceuticals Limited
07 March 2023
MGC Pharmaceuticals Ltd.
Completion of CimetrA(TM) Mechanism of Action study
07 March 2023
ASX, LSE: MXC
Key Highlights:
-- MGC Pharma has completed an in-vitro pre-clinical study on
CimetrA(TM)'s mechanism of action (MoA)
-- The study, which was carried out at the GLP-Certified Science
in Action Lab, in Ness Ziona, Israel, examined the mechanism
underlying the CimetrA(TM)-mediated anti-inflammatory effect on
human Peripheral Blood Mononuclear Cells (PBMC)
-- The study demonstrated the inhibitory effect of CimetrA(TM)
on the mRNA expression and, as a result, on the secretion of IL-32
proteins and the subsequent suppression of inflammation and
inflammatory cytokines
-- Additional findings show that CimetrA(TM) increases
intracellular HO-1 the antioxidant activity in cells, protecting
against oxidative stress that causes the inflammation
-- Further demonstrates CimetrA (TM)'s ability to be extended
into the anti-inflammatory market
MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') a
European based pharmaceutical company specialising in the
production and development of plant inspired medicines, has
completed the pre-clinical study on CimetrA(TM), exploring the
Mechanism of Action (MoA) of the product.
The study was conducted on human Peripheral Blood Mononuclear
Cells (PBMC) crucial in the immune response, the results of which
are consistent with previous reports. The administration of
CimetrA(TM) before and during Lipopolysaccharide (LPS) stimulation
to produce an immune response and induce cytokine generation,
resulted in a significant decrease in IL-32 mRNA expression and a
resulting decrease in inflammation.
As such, we conclude that the presence of the IL-32 mRNA protein
plays a critical role in the secretion of the cytokines (Figure 1),
such as tumour necrosis factor-alpha (TNF-<ALPHA>) and IL-6
(Figure 2), that cause inflammation. Control of this protein is
then the fundamental pathway to manage and reduce inflammation. The
preclinical study demonstrates that the Mechanism of Action in
MGC's core development product, CimetrA(TM) is the suppression of
IL-32 protein via effect on the mRNA expression. The graph below
demonstrates the decreased (up to undetectable values) IL-32A level
after the treatment of the PBMC induced tissue with CimetrA(TM) in
comparison with the baseline (LPS column), Placebo treatment and
not treated control.
Figure 1. Showing secretion of the cytokines in IL-32
Figure 2. Showing secretion of the cytokines in IL-6 in induced
PBMC tissue in different concentrations of CimetrA active
ingredients. RD VA340 - compound used in the current clinical
study, decreased the level of IL-6.
Additional findings in the study showed an increase in
intracellular Heme-Oxygenase-1 (HO-1) levels (Figure 3). HO-1 is an
enzyme which facilitates the breakdown of metabolites in the cell,
enhancing the antioxidant activity and providing protection against
oxidative stress, which can cause inflammation. This is a further
indication as to the CimetrA(TM) MoA and its treatment of
inflammatory disease including COVID-19, seasonal cold and flu,
among others.
Figure 3. Showing an increase in intracellular Heme-Oxygenase-1
(HO-1) levels in induced PBMC tissue in different concentrations of
CimetrA active ingredients. RD VA340 - compound used in the current
clinical study, increased the level of HO-1.
This study is the final preclinical mechanism of action study
and will enable the Company to expand the trials in future to show
its efficacy against further indications. The study results will
form part of the US Food and Drug Administration (FDA) application
to register CimetrA(TM) as an Investigational New Drug (IND). The
trial was carried out at the GLP-certified Science in Action
Laboratory in Ness Ziona, Israel.
Roby Zomer, co-founder and Managing Director of MGC
Pharmaceuticals, commented : "The completion of this study has
advanced our understanding of the biological mechanisms and
demonstrate CimetrA(TM)'s effective in the treatment of
inflammatory disease, which will allow us to open the target market
not only as Covid-19 treatment but to the whole Anti-Inflammatory
treatments, such keeping the relevancy of CimetrA(TM) as more than
just seasonal hype treatment but as long term treatment
offering"
"The data from this study provides critical confirmation in the
pathway to drug development and means that we can further target
the specific biological functions in our formulation."
--Ends--
Authorised for release by the board of directors, for further
information please contact:
MGC Pharmaceuticals Ltd MGC Pharmaceuticals Ltd
Roby Zomer Arron Canicais & Rowan Harland
CEO & Managing Director Company Secretary
+61 8 6382 3390 +61 8 6382 3390
info@mgcpharma.co.uk info@mgcpharma.co.uk
UK Financial and Corporate UK PR Advisors
Advisor Tavistock
SW4 Partners Charles Vivian / Tim Pearson
Rupert Fane / Nilesh Patel +44 207 920 3150
+44 7810 056 104 mgcpharma@tavistock.co.uk
rupert@sw4partners.com / nilesh@sw4partners.com
About MGC Pharma
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based
pharmaceutical company, focused on developing and supplying
accessible and ethically produced plant inspired medicines,
combining in-house research with innovative technologies, with the
goal of finding or producing treatments to for unmet medical
conditions.
The Company's founders and executives are key figures in the
global pharmaceuticals industry and the core business strategy is
to develop and supply high quality plant inspired medicines for the
growing demand in the medical markets in Europe, North America and
Australasia.
MGC Pharma has a robust development pipeline targeting two
widespread medical conditions and has further products under
development.
MGC Pharma has partnered with renowned institutions and academia
to optimise the development of targeted plant inspired medicines,
to be produced in the Company's EU-GMP Certified manufacturing
facilities.
MGC Pharma has a growing patient base in Australia, the UK,
Brazil and Ireland and has a global distribution footprint via an
extensive network of commercial partners meaning that it is poised
to supply the global market.
Follow us through our social media channels:
Twitter: @MGC_Pharma
Facebook: @mgcpharmaceuticals
LinkedIn: MGC Pharmaceuticals Ltd.
Instagram: @mgc_pharma
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDUPUWPWUPWUQM
(END) Dow Jones Newswires
March 07, 2023 02:00 ET (07:00 GMT)
Mgc Pharmaceuticals (LSE:MXC)
Historical Stock Chart
From Apr 2024 to May 2024
Mgc Pharmaceuticals (LSE:MXC)
Historical Stock Chart
From May 2023 to May 2024